Business Context and Reporting Period
Company: Shuttle Pharmaceuticals Holdings, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: June 4, 2023
Reporting Period: Event date June 4, 2023; Signed June 5, 2023.
Context: The Company entered into Amendment No. 1 to an existing Amendment Agreement regarding a Securities Purchase Agreement (SPA) with Alto Opportunity Master Fund, SPC – Segregated Master Portfolio B ("Alto").
Key Financial Metrics
This filing does not report standard operating financial metrics such as revenue, profit, cash flow, or margins. The filing focuses on a specific debt instrument and liquidity event:
- Convertible Note: $4.3 million (Alto Note).
- Warrants: 1,018,079 shares of common stock (Alto Warrant).
- Cash Collateral Released: $2,924,000 (remaining balance of the original $4.0 million cash collateral).
- Future Option: Alto retains the option to purchase up to an additional $10 million in convertible notes (Subsequent Notes).
Material Changes Versus Prior Period
The filing details a material change to the terms of the Transaction Documents originally dated January 11, 2023, and amended on May 11, 2023. Key changes include:
- Removal of Controlled Account Requirement: Section 15(q) of the Note, which required the Company to hold Cash Collateral in a Controlled Account Agreement, is no longer applicable.
- Liquidity Release: Alto stipulated the release of the remaining $2,924,000 in Cash Collateral to the Company, effectively releasing the full amount of the original collateral.
- Future Terms: Any future Subsequent Notes (up to $10 million) will omit Section 15(q), meaning no controlled accounts will be required for those instruments.
Guidance, Outlook, and Risks
Management Commentary: The filing confirms the execution of the amendment to improve liquidity by releasing restricted cash. No specific forward-looking guidance on revenue or clinical milestones is provided in this document.
Risks and Contingencies:
- The Company remains subject to the terms of the $4.3 million convertible note and the associated warrant.
- Alto retains the option to purchase additional debt instruments up to $10 million, which could impact future capital structure if exercised.
Important Facts for Investor Verification
- Verify the immediate impact of the $2,924,000 cash release on the Company's current liquidity position.
- Confirm the status of the $4.3 million convertible note and the 1,018,079 warrants held by Alto.
- Monitor whether Alto exercises the option to purchase the additional $10 million in Subsequent Notes.
- Review the full text of Amendment No. 1 (Exhibit 10.1) for any other covenants or conditions not summarized in the 8-K.